AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 26.39 |
Market Cap | 149.64B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 0.75 |
PE Ratio (ttm) | 35.21 |
Forward PE | n/a |
Analyst | Hold |
Ask | 26.41 |
Volume | 21,869,050 |
Avg. Volume (20D) | 43,218,409 |
Open | 26.81 |
Previous Close | 26.80 |
Day's Range | 26.27 - 26.87 |
52-Week Range | 24.48 - 31.54 |
Beta | undefined |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable an...
Analyst Forecast
According to 13 analyst ratings, the average rating for PFE stock is "Hold." The 12-month stock price forecast is $32, which is an increase of 21.19% from the latest price.
Next Earnings Release
Analysts project revenue of $17.13B, reflecting a 20.22% YoY growth and earnings per share of 0.46, making a 360.00% increase YoY.